glioblastoma
multiform
gbm
common
aggress
type
brain
cancer
median
length
surviv
time
approxim
month
follow
diagnosi
gbm
character
anaplasia
nuclear
atypia
cellular
pleomorph
mitot
activ
importantli
altern
phase
rapid
prolifer
aggress
invas
surround
brain
tissu
lead
inevit
critic
recurr
even
surgic
resect
main
tumor
mass
mainstay
treatment
gbm
surgeri
follow
radiotherapi
chemotherapi
despit
advanc
approach
glioma
cell
still
invad
neighbor
tissu
beyond
detect
lead
tumor
recurr
high
probabl
main
treatment
failur
also
encourag
research
investig
use
innov
treatment
first
line
therapi
fail
order
improv
clinic
outcom
tumor
microenviron
tme
glioma
cell
encount
mani
challeng
includ
hypoxia
acid
limit
nutrient
avail
maintain
rapid
growth
tumor
cell
need
adapt
biochem
chang
modifi
metabol
activ
increas
glycolysi
even
presenc
oxygen
process
call
warburg
effect
requir
consum
consider
amount
glucos
tricarboxyl
acid
cycl
kreb
cycl
play
import
role
breakdown
organ
fuel
molecul
surviv
nonhypox
normal
differenti
cell
molecul
includ
glucos
fatti
acid
amino
acid
differenti
cell
favor
type
metabol
effici
term
atp
product
tumor
cell
adopt
ineffici
aerob
glycolysi
produc
rel
larg
amount
wast
product
form
lactic
acid
may
provid
cancer
cell
advantag
depend
oxygen
energi
sourc
especi
hostil
tumor
microenviron
thu
lead
longer
surviv
inhibit
glycolysi
may
also
prevent
drug
resist
thu
better
understand
metabol
pathway
may
lead
better
treatment
option
clinic
outcom
develop
strategi
metabol
adapt
angiogenesi
migrat
critic
cancer
cell
order
surviv
metabol
stress
ensur
enough
nutrient
suppli
tumor
mass
accumul
glucos
suppli
may
fluctuat
due
heterogen
biochem
biophys
condit
therefor
adequ
cellular
respons
glucos
withdraw
critic
cancer
cell
surviv
cancer
cell
activ
monophosph
activ
protein
kinas
ampk
pathway
metabol
stress
master
cellular
sensor
energi
avail
enhanc
glucos
uptak
conserv
energi
thu
avoid
cell
death
microrna
also
abbrevi
mirna
approxim
nucleotid
singlestrand
noncod
ribonucl
acid
rna
known
regul
gene
express
dysregul
microrna
express
link
oncogen
tumor
suppressor
activ
sever
type
cancer
includ
gbm
alter
mirna
express
contribut
tumorigenesi
godlewski
et
al
identifi
interest
mechan
glioma
cell
migrat
prolifer
wherein
particular
microrna
counterpart
ampk
complex
determin
whether
cell
favor
growth
expens
invas
convers
moreov
also
identifi
potenti
feedback
loop
allow
sustain
robust
respons
glucos
withdraw
found
high
normal
glucos
condit
upregul
lead
downregul
ampk
complex
lead
elev
prolifer
decreas
migrat
glioma
cell
ii
glucos
withdraw
induc
downregul
upregul
ampk
promot
cell
migrat
reduc
prolifer
mathemat
model
develop
kim
et
al
describ
effect
core
control
system
cell
prolifer
migrat
glioblastoma
explain
respons
high
low
glucos
level
well
mutual
antagon
ampk
complex
concentr
kim
et
al
extend
model
includ
dynam
mammalian
target
rapamycin
mtor
protein
kinas
link
protein
well
cell
cycl
dynam
form
core
control
system
mutual
antagon
ampk
predict
mathemat
model
confirm
recent
experi
exampl
ansari
et
al
recent
found
transcript
gbm
cell
induc
unrestrict
activ
transcript
factor
offici
gene
symbol
presenc
abund
glucos
result
ampk
inhibit
direct
target
complex
ii
level
inhibit
phosphoryl
inactiv
ampk
respons
glucos
depletioninduc
metabol
stress
lead
reciproc
neg
feedback
loop
ampk
case
suppress
turn
lead
sustain
ampk
activ
robust
respons
glucos
withdraw
gbm
cell
multiscal
mathemat
model
also
predict
cycl
pattern
glioma
cell
respons
fluctuat
glucos
uptak
tumor
microenviron
core
control
system
predict
bistabl
hysteresi
bifurc
delay
downregul
activ
along
certain
molecular
pathway
would
induc
glioma
cell
stay
longer
prolif
phase
despit
rel
low
glucos
concentr
make
mechan
therapeut
target
cell
cycl
repres
integr
seri
event
regul
complex
process
includ
cell
prolifer
cell
divis
dna
replic
regul
complex
hierarchi
genet
metabol
network
involv
sever
transit
state
vari
length
checkpoint
stage
cell
cycl
follow
synthesi
phase
period
dna
replic
occur
ii
gap
phase
protein
requir
mitosi
produc
iii
mitosi
phase
period
chromatin
condens
nuclear
envelop
breakdown
nebd
chromatid
separ
cytokinesi
happen
iv
gap
phase
gene
necessari
dna
replic
activ
protein
agent
phase
progress
accumul
v
rest
phase
state
cell
exit
cell
cycl
enter
phase
quiescenc
rel
inact
progress
mammalian
cell
cycl
tightli
regul
coordin
activ
cyclindepend
kinas
cdk
famili
cdk
posit
regul
cyclin
neg
cdk
inhibitor
cdki
protein
cancer
cell
cyclin
overexpress
cdki
underexpress
result
dysregul
cell
cycl
promot
uncontrol
cell
growth
tyson
novak
identifi
transit
two
stabl
steadi
state
cellcycl
phase
describ
use
kinet
relat
model
control
chang
cell
mass
standard
gbm
treatment
surgeri
follow
chemotherapi
radiotherapi
howev
even
best
circumst
mean
surviv
diseas
year
poor
outcom
standard
care
treatment
due
topograph
diffus
natur
diseas
time
diagnosi
typic
gbm
cell
may
wide
spread
throughout
brain
tissu
increas
potenti
recurr
thu
annihil
distant
tumor
satellit
implaus
despit
surgic
remov
essenti
tumor
seen
enhanc
mri
scan
know
exact
margin
tumor
mass
real
patient
inde
daunt
task
studi
assum
major
tumour
mass
surgic
remov
infiltr
tumor
cell
near
surgic
site
object
prevent
glioma
cell
diffus
surround
brain
tissu
local
approach
util
glioma
cell
invas
block
keep
prolif
phase
also
attempt
limit
excess
growth
second
surgeri
analyt
tool
primarili
base
framework
optim
control
theori
success
use
make
inform
decis
involv
biolog
model
optim
treatment
strategi
human
immunodefici
viru
hiv
model
tuberculosi
cardiopulmonari
resuscit
cpr
techniqu
optim
control
theori
also
appli
core
control
system
determin
intraven
glucos
andor
drug
infus
protocol
least
possibl
cost
variou
circumst
de
lo
rey
et
al
recent
kim
et
al
develop
intracellular
signal
pathway
model
extend
core
control
system
includ
cell
cycl
dynam
work
potenti
control
problem
formul
order
maintain
high
level
mtor
low
level
ampk
induc
cell
prolifer
prohibit
cell
motil
invas
neighbor
tissu
glucos
level
key
regul
activ
also
activ
mtor
downstream
signal
pathway
glucos
intraven
infus
consid
upregul
mtor
concentr
certain
threshold
valu
addit
drug
suppress
inhibitori
effect
mtor
ampk
complex
incorpor
drug
administ
concomitantli
altern
glucos
secondari
intraven
infus
control
given
dose
rate
glucos
drug
intraven
administr
regul
upstream
downstream
signal
pathway
respect
solut
optim
control
problem
aim
determin
infus
protocol
minim
glucos
drug
amount
least
administr
cost
henc
glucos
drug
level
regul
prevent
rapid
tumour
growth
hyperglycemia
drug
complic
result
propos
plausibl
glucos
drug
intraven
infus
control
indic
time
administr
frequenc
number
administr
dosag
glucos
drug
per
infus
current
studi
first
present
cycl
intracellular
signal
pathway
develop
kim
et
al
drug
modul
incorpor
upregul
mtor
activ
induc
cell
prolifer
optim
control
problem
formul
goal
activ
mtor
level
glucos
drug
intraven
infus
two
differ
infus
protocol
explor
name
concomit
altern
glucos
drug
intraven
administr
optim
solut
two
strategi
present
result
frequenc
dosag
per
infus
total
glucos
drug
amount
rel
cost
incur
administr
compar
conclus
section
discuss
summar
optim
control
result
provid
outlook
futur
research
direct
section
present
basic
compon
intracellular
signal
pathway
tumor
cell
contain
core
control
cell
cycl
pathway
develop
kim
et
al
incorpor
drug
block
inhibitori
pathway
mtor
ampk
complex
core
control
model
identifi
key
mechan
determin
molecular
switch
prolif
migratori
phase
respons
fluctuat
glucos
drug
level
simplifi
signal
pathway
consist
five
key
determin
intracellular
structur
name
glucos
level
g
level
ampk
complex
activ
mtor
concentr
r
drug
level
intracellular
cell
cycl
dynam
develop
tyson
novak
includ
essenti
interact
regul
control
model
captur
kinet
chemic
process
within
cell
product
destruct
differ
molecul
interact
transit
two
main
steadi
state
phase
cell
cycl
describ
use
kinet
relat
model
control
chang
cell
mass
powathil
et
al
modifi
model
use
equival
mammalian
protein
name
cdkcyclin
b
complex
cycb
complex
activ
form
complex
total
complex
activ
form
protein
cell
mass
mass
also
includ
effect
chang
oxygen
dynam
macroscop
level
activ
inactiv
result
chang
cell
cycl
length
addit
cell
cycl
inhibitori
effect
gene
incorpor
kim
et
al
propos
link
control
system
cell
cycl
dynam
provid
mechan
drive
cell
cycl
undergo
quiescent
stage
depend
concentr
level
mtor
fig
depict
detail
schemat
diagram
intracellular
signal
network
includ
ampk
complex
mtor
key
player
cell
cycl
modul
cycb
kinet
interpret
arrow
hammerhead
repres
induct
inhibit
signal
network
respect
dimensionless
diagram
core
control
ampk
complex
mtor
link
cell
cycl
depict
fig
note
ug
ud
sourc
glucos
drug
decay
rate
respect
control
exogen
signal
sourc
ampk
complex
mtor
respect
inhibit
strength
denot
decay
shown
high
normal
glucos
concentr
yield
express
level
downregul
ampk
complex
upregul
mtor
lead
elev
cell
prolifer
reduc
migrat
low
glucos
level
lead
downregul
activ
upregul
ampk
complex
downregul
mtor
reduc
cell
prolifer
induc
migrat
surround
brain
tissu
effect
variou
glucos
level
regul
core
control
depict
fig
kim
et
al
develop
core
control
system
glioma
cell
migrat
prolifer
use
regulatori
network
key
molecul
ampk
follow
observ
experi
regulatori
system
eq
includ
mutual
antagonist
loop
ampk
complex
respons
high
low
glucos
level
g
genet
toggl
switch
induc
monost
bistabl
system
character
prolifer
critic
cell
infiltr
gbm
cell
brain
followup
studi
includ
mtor
r
cell
cycl
modul
mutual
antagon
bistabl
system
play
critic
role
develop
antiinvas
strategi
mutual
antagonist
feedback
loop
wellstudi
bistabl
properti
use
mathemat
model
refer
instanc
studi
genet
toggl
switch
escherichia
coli
mutual
inhibitori
loop
repressor
repressor
shown
induc
bistabl
addit
monost
statu
particular
lu
et
al
theoret
studi
mirbas
regul
show
regulatori
network
includ
mutual
inhibit
feedback
circuit
induc
tristabl
circuit
epithelialhybridmesenchym
fate
differenti
detail
analysi
selfactiv
tristabl
stateinduc
toggl
switch
gener
multist
genet
circuit
found
biolog
network
without
mutual
inhibit
also
induc
bistabl
system
instanc
aguda
et
al
investig
role
mirna
regul
cell
cycl
cancer
zone
emerg
bistabl
toggl
switch
feedback
loop
myc
studi
consid
drug
suppress
inhibitori
effect
mtor
ampk
complex
inhibit
strength
given
larg
small
make
drdt
larg
thu
presenc
drug
upregul
mtor
activ
could
eventu
lead
cell
prolifer
fig
illustr
mtor
bifurc
curv
observ
increas
drug
concentr
shift
hysteresi
curv
upward
keep
bistabl
window
henc
higher
drug
level
glucos
concentr
mtor
activ
prompt
elev
cell
growth
core
control
system
develop
kim
colleagu
bistabl
regim
main
variabl
emerg
respons
glucos
level
shown
exist
size
bistabl
window
wb
depend
essenti
paramet
may
disappear
perturb
paramet
shown
later
fig
key
paramet
sensit
creation
destroy
bistabl
paramet
achiev
equilibrium
continu
curv
comput
vari
glucos
concentr
g
bifurc
point
detect
label
lp
cp
limit
cusp
point
respect
fig
illustr
hysteresi
diagram
g
r
differ
valu
order
obtain
cusp
point
cp
fold
continu
comput
start
limit
point
two
paramet
g
activ
result
codim
bifurc
paramet
g
vari
along
curv
point
limit
point
equilibrium
curv
correspond
valu
depict
fig
cusp
point
give
threshold
valu
thm
tha
thr
matlab
softwar
matcont
use
numer
continu
bifurc
studi
continu
discret
dynam
system
govern
model
equat
dimensionless
intracellular
signal
dynam
describ
follow
ordinari
differenti
equat
cycb
hif
cycb
dt
masss
cycb
cycb
masss
cycb
masss
mad
masss
cycb
mass
mass
mass
cell
cycl
dynam
regulatori
core
control
system
link
variabl
call
pseudomass
masss
given
masss
mass
oxygen
dynam
describ
hif
growth
rate
express
probabl
densiti
function
uniform
distribut
growth
rate
formul
introduc
cell
cycl
heterogen
length
hr
account
natur
variabl
cell
growth
rate
nonsynchron
popul
model
paramet
system
list
tabl
current
model
formul
mtor
r
activatedinactiv
way
addit
r
link
core
control
system
cell
cycl
dynam
via
pseudomass
masss
influenc
cell
mass
mass
intracellular
protein
refer
eq
therefor
glucos
suppli
high
r
upregul
prolif
phase
upregul
downregul
masss
mass
yield
typic
cell
cycl
see
fig
hand
glucos
suppli
low
r
downregul
migratori
phase
downregul
upregul
masss
exce
mass
influenc
cell
enter
rest
phase
let
us
assum
glucos
g
drug
regul
intraven
infus
period
administ
illustr
purpos
consid
infus
everi
maximum
dosag
unit
refer
regular
infus
uj
intracellular
dynam
regular
infus
seen
fig
sinc
glucos
drug
level
oscil
follow
r
also
period
fluctuat
around
threshold
thm
thr
seen
fig
note
r
cross
threshold
valu
respect
peak
pseudomass
gener
thu
infer
peak
indic
cell
migrat
sinc
r
level
respect
threshold
valu
shown
fig
trajectori
core
control
concentr
space
switch
prolifer
migrat
region
closer
look
intracellular
cell
cycl
protein
mass
masss
dynam
illustr
fig
note
regular
infus
significantli
perturb
cell
cycl
dynam
stimul
sever
cell
divis
see
mass
profil
cell
migrat
see
masss
inde
fluctuat
glucos
level
microenviron
lead
dichotomi
grow
go
dynam
glioblastoma
cell
yield
bigger
tumor
mass
report
even
presenc
fluctuat
drug
concentr
keep
cell
prolifer
phase
current
investig
aim
regul
amount
glucos
drug
infus
upregul
mtor
threshold
valu
induc
cell
prolifer
avoid
migrat
neighbor
tissu
model
approach
util
optim
control
theori
identifi
infus
administr
protocol
let
ug
ud
control
system
repres
dose
rate
glucos
drug
intraven
administr
respect
two
differ
administr
protocol
examin
name
concomit
altern
glucos
drug
infus
follow
object
function
jcon
ug
ud
r
dt
jalt
r
r
dt
respect
r
denot
level
mtor
concentr
respect
paramet
weight
factor
measur
rel
cost
base
maxim
mtor
r
administ
glucos
drug
intraven
infus
specifi
time
interv
respect
control
cost
model
linear
combin
quadrat
term
object
find
optim
infus
regimen
glucos
drug
administr
denot
ug
ud
object
function
satisfi
jcon
ug
ud
ug
ud
jalt
ug
ud
ug
ud
ug
ud
ud
ug
ud
bound
control
repres
limit
dose
rate
glucos
drug
administr
assum
ampk
mtor
respons
regul
glucos
level
influenc
drug
level
control
strategi
deal
find
optim
control
regimen
glucos
drug
intraven
infus
also
note
exist
optim
control
guarante
standard
result
control
theori
maxim
problem
necessari
convex
integrand
object
function
hold
therefor
proceed
appli
pontryagin
maximum
principl
iter
method
use
solv
optim
system
twopoint
boundari
valu
problem
initi
condit
state
variabl
termin
condit
adjoint
numer
simul
obtain
use
fourthord
iter
rungekutta
method
given
initi
condit
guess
control
state
equat
solv
use
forward
scheme
correspond
adjoint
equat
solv
use
backward
scheme
transvers
condit
control
updat
use
convex
combin
previou
control
valu
character
commonli
refer
sweep
method
fbsm
shown
converg
detail
optim
control
studi
found
appendix
kim
et
al
see
fig
supplementari
appendix
file
sensit
analysi
core
control
model
equat
r
eq
perform
order
determin
paramet
mostleast
influenc
refer
output
main
variabl
core
control
paramet
consid
assess
correspond
influenc
ampk
mtor
activ
infer
activ
enhanc
increas
glucos
signal
g
autocatalyt
product
rate
paramet
neg
correl
ampk
activ
due
mutual
antagonist
mechan
ampk
complex
addit
ampk
activ
upregul
increas
signal
sourc
autocatalyt
rate
ampk
complex
model
also
note
increas
inhibit
strength
mtor
ampk
downregul
mtor
level
similar
fashion
strongli
posit
correl
mtor
level
littl
correl
g
time
work
sensit
analysi
carri
determin
model
paramet
consequenti
effect
achiev
inhibit
bistabl
g
r
method
adapt
rang
paramet
select
divid
n
interv
uniform
length
paramet
interest
partial
rank
correl
coeffici
prcc
valu
comput
order
obtain
prcc
valu
latin
hypercub
sampl
lh
stratifi
sampl
without
replac
techniqu
chosen
prcc
valu
rang
sign
determin
whether
chang
paramet
valu
promot
suppress
bistabl
follow
algorithm
perform
assign
probabl
distribut
min
max
paramet
let
n
number
sampl
select
divid
interv
min
max
n
equiprob
subinterv
draw
independ
sampl
subintervalassembl
lh
matrix
l
wherein
row
l
repres
uniqu
combin
paramet
sampl
without
replacementfor
row
lh
matrix
l
solv
mtor
r
term
glucos
g
check
bistabl
window
wb
bistabl
exist
assign
output
variabl
wb
matrix
els
assign
matric
l
obtain
lr
yr
ranktransform
mean
replac
valu
rank
data
sort
lowest
highest
eg
smallest
valu
assign
rank
tie
valu
assign
averag
rankfix
paramet
encod
jth
column
matrix
lr
form
follow
linear
regress
model
use
data
matric
lr
yr
respect
comput
residu
input
paramet
output
remov
linear
effect
input
parametersobtain
prcc
use
ycov
var
var
repeat
step
remain
paramet
fig
show
sensit
prcc
valu
model
paramet
promot
destroy
bistabl
illustr
chang
autocatalyt
product
rate
inhibit
strength
ampk
complex
enhanc
bistabl
contrari
hilltyp
coeffici
regul
ampk
respons
lose
bistabl
note
due
model
structur
upregul
turn
increas
mtor
suppress
ampk
activ
paramet
promot
ampk
complex
downregul
mtor
howev
paramet
littl
sensit
emerg
destruct
bistabl
bistabl
core
control
system
depend
geometr
structur
nullclin
particular
bistabl
aris
anullclin
ie
intersect
three
distinct
point
produc
one
unstabl
two
stabl
steadi
state
nullclin
intersect
three
time
due
sigmoid
influenc
catalyt
rate
rate
must
proportion
given
glucos
g
level
otherwis
nullclin
intersect
bistabl
condit
shown
genet
toggl
switch
e
coli
fig
depict
anullclin
differ
g
level
variou
valu
bifurc
curv
region
bistabl
specif
g
level
depict
fig
given
circumst
show
signific
sensit
bistabl
system
contrari
affect
rnullclin
illustr
fig
sever
valu
r
anullclin
intersect
one
point
lead
singl
steadi
state
effect
anullclin
also
intersect
produc
monost
henc
show
insignific
consequ
achiev
bistabl
see
fig
follow
numer
experi
assum
initi
glioma
cell
growth
phase
probabl
occurr
post
primari
tumour
surgeri
thm
tha
r
thr
also
consid
glucos
drug
administ
exogen
intraven
infus
weight
paramet
use
default
valu
unless
specifi
strategi
glucos
drug
infus
administ
simultan
particular
control
ug
ud
infus
thu
refer
concomit
control
assum
drug
consider
block
inhibitori
pathway
mtor
ampk
complex
neglig
side
effect
inconsequenti
chemic
reaction
glucos
order
determin
effici
strategi
concomit
infus
protocol
glucos
drug
administ
concurr
initi
time
hour
use
numer
scheme
fbsm
infus
spontan
increas
glucos
drug
concentr
depict
fig
b
consequ
mtor
level
upregul
ampk
complex
downregul
shown
fig
closer
look
control
curv
show
ug
ud
decreas
ti
suggest
glucos
drug
dose
rate
decreas
time
ti
lead
decreas
glucos
drug
concentr
due
consumpt
decay
accordingli
mtor
level
decreas
ampk
complex
increas
cross
threshold
valu
thm
fbsm
appli
next
hour
suggest
time
next
concomit
administr
profil
monitor
subsequ
procedur
track
profil
appli
fbsm
hour
repeat
specifi
time
durat
thu
number
concomit
administr
determin
import
note
keep
level
threshold
valu
consequ
confin
ampk
mtor
level
correspond
threshold
valu
respect
see
fig
fig
depict
intracellular
dynam
concomit
glucos
drug
control
fig
observ
mtor
level
threshold
valu
masss
mass
concomit
control
trajectori
concentr
profil
restrict
prolifer
region
shown
fig
time
cours
cell
cycl
variabl
concomit
control
illustr
fig
seen
concomit
control
induc
fewer
mass
divis
period
compar
regular
infus
mass
divis
see
fig
note
well
concomit
control
mass
concentr
increas
divis
suppos
concurr
glucos
drug
administr
plausibl
due
unwant
chemic
reaction
propos
anoth
control
strategi
administ
glucos
ug
drug
ud
infus
altern
initi
time
glucos
infus
obtain
solv
optim
control
problem
use
numer
scheme
fbsm
hour
next
drug
infus
attain
next
hour
similar
manner
henc
control
ug
ud
appli
one
subsequ
level
track
cross
threshold
valu
glucos
infus
ug
drug
infus
ud
administ
altern
similar
fashion
specifi
durat
administr
thu
time
next
altern
infus
determin
track
level
strategi
refer
simpli
altern
control
infus
protocol
shown
fig
b
note
glucos
infus
increas
level
drug
infus
activ
mtor
activ
keep
ampk
downregul
depict
fig
intracellular
dynam
altern
control
illustr
fig
shown
fig
mtor
level
stay
threshold
valu
masss
mass
fig
depict
trajectori
confin
prolifer
region
fig
exhibit
time
cours
cell
cycl
variabl
altern
control
concomit
altern
control
strategi
abl
sustain
elev
mtor
level
threshold
valu
ampk
level
threshold
valu
also
shown
trajectori
restrain
prolifer
region
prohibit
cell
migrat
number
cell
divis
reduc
slightli
higher
mass
concentr
divis
compar
regular
infus
lower
compar
constant
intermedi
high
glucos
concentr
section
compar
cost
effici
propos
strategi
term
frequenc
administr
dose
per
infus
total
glucos
drug
amount
rel
cost
per
infus
total
cost
incur
administr
follow
result
time
simul
durat
consid
hour
recal
paramet
weight
factor
associ
object
function
repres
measur
cost
involv
administr
glucos
ug
drug
ud
infus
respect
also
includ
dosag
type
brand
medic
fee
administr
etc
fig
show
cost
glucos
administr
becom
expens
increas
valu
fix
drug
administr
cost
frequenc
concomit
altern
infus
increas
howev
observ
frequenc
administr
increas
optim
glucos
dose
per
infus
decreas
drug
dose
per
infus
increas
see
fig
increas
drug
dosag
compens
decreas
glucos
dosag
order
keep
mtor
activ
upregul
lead
cell
prolifer
contrari
drug
administr
cost
increas
increas
valu
fix
glucos
administr
cost
frequenc
administr
remain
almost
constant
depict
fig
glucos
dose
per
infus
almost
drug
dose
per
infus
decreas
increas
illustr
fig
note
frequenc
concomit
infus
control
alway
lower
altern
infus
control
addit
drug
glucos
dose
per
infus
concomit
control
alway
slightli
less
altern
control
increas
glucos
administr
cost
increas
fix
drug
administr
cost
total
amount
glucos
use
control
strategi
gener
decreas
except
high
valu
depict
fig
total
amount
drug
increas
see
fig
hand
drug
administr
becom
expens
increas
valu
fix
glucos
administr
cost
total
amount
glucos
dosag
almost
constant
slightli
increas
concomit
control
shown
fig
total
drug
amount
decreas
seen
fig
illustr
fig
concomit
control
use
less
total
amount
glucos
altern
control
contrarili
concomit
administr
consum
total
drug
amount
compar
altern
control
except
possibl
high
glucos
administr
cost
see
fig
fig
reflect
rel
cost
per
infus
total
administr
cost
glucos
drug
infus
incur
concomit
altern
control
fix
drug
administr
cost
rel
glucos
cost
per
infus
total
administr
cost
increas
increas
note
altern
control
cost
glucos
alway
higher
concomit
infus
see
fig
b
rel
total
administr
cost
concomit
infus
slightli
increas
compar
altern
control
increas
altern
control
incur
cost
higher
glucos
administr
cost
illustr
fig
c
hand
drug
administr
cost
increas
rel
glucos
cost
per
infus
total
administr
cost
almost
constant
seen
fig
b
rel
total
cost
altern
control
higher
concomit
control
increas
rel
drug
cost
per
infus
total
administr
cost
decreas
fig
c
sinc
total
drug
dosag
also
decreas
shown
fig
case
seen
drug
administr
cost
altern
control
gener
lower
concomit
control
observ
fig
concomit
blue
altern
orang
control
trajectori
space
restrict
smaller
region
avoid
aggress
invas
rapid
prolifer
unwant
drug
complic
strategi
achiev
goal
keep
mtor
upregul
induc
cell
prolifer
thu
avoid
aggress
cell
migrat
import
note
propos
optim
control
infus
glucos
drug
level
regul
prevent
excess
cell
divis
tumor
growth
consequ
strategi
suggest
safer
infus
administr
prevent
hyperglycemia
diabet
patient
risk
drug
complic
tabl
provid
averag
frequenc
dosag
rel
cost
concomit
altern
control
strategi
simul
time
period
switch
behavior
glioblastoma
cell
prolifer
invas
phase
highli
influenc
fluctuat
glucos
level
respons
high
glucos
suppli
mtor
upregul
ampk
complex
downregul
induc
cell
growth
contrari
low
glucos
level
upregul
ampk
complex
downregul
mtor
promot
cell
migrat
mutual
antagonist
mechan
mtor
ampk
complex
cell
strateg
metabol
adapt
support
surviv
cancer
cell
even
nutrientdepriv
microenviron
addit
rapid
prolifer
glioblastoma
cell
aggress
invas
surround
tissu
major
caus
treatment
failur
despit
advanc
medic
imag
technolog
mri
pet
glioblastoma
cell
spread
beyond
detect
lead
tumor
recurr
within
cm
resect
caviti
even
surgic
remov
malign
glioblastoma
glioma
cell
capabl
deform
cell
membran
nucleu
cell
infiltr
narrow
gap
normal
glial
cell
brain
tissu
upregul
myosin
ii
along
actin
bundl
exact
migratori
pattern
still
poorli
understood
invas
glioma
cell
prefer
white
matter
blood
vessel
wide
rang
speed
rang
show
sometim
saltatori
pattern
migrat
direct
brain
predict
tumour
invas
direct
nearbi
tissu
may
help
defin
exact
boundari
focal
treatment
surgeri
radiosurgeri
prevent
futur
growth
recurr
exampl
medic
doctor
could
determin
specif
locat
radiat
target
volum
use
rough
estim
cm
direct
guidanc
commonli
done
today
assum
migratori
cell
local
near
surgeri
site
one
possibl
approach
keep
cell
prolif
phase
prevent
invad
brain
tissu
combin
transport
therapeut
drug
near
blood
vessel
result
tumor
mass
visibl
succeed
surgeri
kill
prolif
tumor
cell
blood
site
studi
consid
intracellular
dynam
cycl
signal
pathway
model
develop
recent
kim
et
al
incorpor
model
drug
compon
block
inhibitori
pathway
mtor
ampk
complex
drug
target
upregul
mtor
activ
enhanc
cell
prolifer
focu
current
work
regul
upstream
signal
pathway
via
glucos
infus
activ
control
downstream
pathway
cell
cycl
via
drug
infus
enhanc
mtor
activ
optim
control
problem
formul
goal
keep
high
level
mtor
induc
cell
growth
reduc
invas
surround
tissu
framework
optim
control
theori
two
administr
strategi
explor
achiev
goal
minim
cost
incur
glucos
drug
administr
control
strategi
investig
studi
concomit
infus
control
altern
glucos
drug
infus
control
strategi
abl
switch
prolif
mode
glioblastoma
cell
turn
migratori
mode
cell
cycl
regul
fewer
mass
divis
restrict
rapid
growth
numer
result
show
concomit
control
fewer
infus
lesser
glucos
dosag
cheaper
administr
cost
howev
glucos
drug
pose
unwant
chemic
reaction
concurr
administr
altern
control
would
benefici
lower
drug
amount
usag
mathemat
model
core
control
base
goorgrow
hypothesi
support
experi
gbm
cell
howev
rang
bistabl
behavior
indic
goandgrow
program
propos
cancer
glioma
case
goorgrow
hypothesi
long
suggest
addit
goorgrow
mechan
glioma
consist
bulki
prolif
core
center
highli
invas
individu
cell
outer
rim
sequenti
transit
prolif
invas
phenotyp
character
tumor
progress
may
lead
faster
growth
least
microscop
level
migrationprolifer
phenotyp
appear
mutual
exclus
characterist
differ
time
frame
suggest
vivo
imag
data
glioma
cell
migrat
saltatori
fashion
glioma
cell
shown
paus
short
period
time
hour
cell
divis
daughter
cell
begin
move
gal
et
al
experiment
observ
phenotyp
switch
happen
differ
extracellular
environ
prolif
type
soft
agar
via
activ
myc
signal
pathway
respons
hepatocyt
growth
factor
hgf
ii
infiltr
type
matrigel
ra
signal
pathway
respons
hgf
recent
dhruv
et
al
also
affirm
role
activ
key
molecul
dichotomi
prolifer
invas
cmyc
prolif
core
radial
dispers
invas
region
gbm
tumor
respect
glial
cell
also
interact
gbm
tumor
cell
phenotyp
switch
gbm
cell
cell
migrat
activ
prolifer
although
experi
mathemat
model
support
goorgrow
hypothesi
certain
altern
mechan
goandgrow
occur
heterogen
tme
real
patient
mansuri
et
al
instanc
illustr
individu
glioma
cell
mix
group
prolif
invas
phenotyp
depend
genotyp
counter
part
tumor
microenviron
similar
conceptu
studi
epithelialtomesenchym
transit
emt
mesenchymaltoepitheli
transit
met
give
hint
complex
complex
regul
two
phenotyp
glioma
tme
might
poss
simpl
goorgrow
dogma
increas
number
evid
suggest
goorgrow
model
similar
molecular
basi
emt
instanc
hgf
major
regul
emt
also
provid
strong
stimuli
gbm
invas
upregul
met
activ
well
activ
signal
pathway
report
mesenchym
gbm
metastat
cancer
experiment
observ
suggest
metastat
epitheli
cancer
mesenchym
gbm
drive
common
mechan
regul
phenotyp
transit
invas
prolifer
suggest
possibl
goandgrow
mechan
emt
paradigm
gbm
extens
studi
relev
progress
diseas
due
differ
origin
rare
metastasi
glioma
studi
experiment
need
done
better
understand
fundament
principl
paper
take
account
key
microenvironment
factor
endogen
immun
dynam
includ
nk
cell
macrophag
major
signal
network
myc
angiogenesi
biophys
interact
tumor
cell
blood
vessel
ecm
remodel
therapi
growth
factor
epiderm
growth
factor
fibroblast
growth
factor
transform
growth
may
play
critic
role
prolifer
progress
aggress
invas
glioma
develop
anticanc
strategi
exampl
endogen
nk
cell
may
interfer
oncolyt
viru
combin
therapi
gbm
exogen
nk
cell
increas
antitumor
efficaci
illustr
complex
natur
tumor
microenviron
recent
mtor
consid
master
regul
cell
growth
recogn
good
therapeut
target
therapi
glioblastoma
recent
studi
found
withaferin
temozolomid
induc
apoptosi
reduc
drug
resist
cell
cycl
arrest
intrins
extrins
apoptot
signal
pathway
detail
analysi
experi
necessari
interestingli
radiat
shown
indirectli
promot
export
lactat
extracellular
space
inhibit
signal
pathway
involv
radiationinduc
invas
cancer
cell
hand
microgliamacrophag
induc
matrix
remodel
glioma
cell
invas
sinc
signal
shown
contribut
tumor
associ
macrophag
tam
bind
shown
enhanc
spread
macrophag
thu
promot
glioma
cell
invas
therefor
better
understand
signal
network
macrophag
would
lead
develop
block
aggress
infiltr
cancer
cell
signal
pathway
apoptosi
necroptosi
import
part
oncolyt
viru
ov
therapi
tumor
extracellular
matrix
ecm
play
signific
role
regul
glioma
invas
brain
tissu
well
ov
spread
exampl
cspg
one
major
tumor
ecm
brain
character
invas
noninvas
glioma
complex
tme
microglia
astrocyt
mechan
interact
cspg
tumor
cell
hybrid
model
associ
optim
control
strategi
adapt
take
account
import
intracellular
signal
well
cell
popul
dynam
tissu
dynam
better
understand
variou
role
compon
tumor
microenviron
may
provid
better
antiinvas
strategi
glioma
cell
howev
mathemat
model
work
first
step
toward
experimentalclin
investig
optim
antiinvas
strategi
gbm
incorpor
microenvironment
compon
address
issu
futur
work
